Tc 99m duramycin

Drug Profile

Tc 99m duramycin

Alternative Names: Tc-99m-duramycin; Technetium 99m duramycin; Technetium duramycin

Latest Information Update: 29 Jul 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Medical College of Wisconsin
  • Developer Molecular Targeting Technologies
  • Class Cardiovascular therapies; Heavy metals; Imaging agents; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Technetium compounds
  • Mechanism of Action Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer; Cardiovascular disorders; Inflammation

Highest Development Phases

  • Preclinical Cancer; Cardiovascular disorders; Inflammation

Most Recent Events

  • 29 Jul 2015 Tc 99m duramycin is available for licensing in World as of 29 Jul 2015. http://www.mtarget.com/
  • 15 May 2015 Preclinical trials in Cancer (Diagnosis) in USA (IV)
  • 15 May 2015 Preclinical trials in Cardiovascular disorders (Diagnosis) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top